Article Text

PDF

OHP-077 The Role of Pharmacists in an Italian Model of Economic Sustainability and Innovative Treatments
  1. S di Pietro1,
  2. M Salanitro2,
  3. F Rapisarda3
  1. 1Azienda Sanitaria Provinciale Siracusa, Hospital Pharmacy Lentini/Pharmacy Department, Lentini, Italy
  2. 2Azienda Sanitaria Provinciale Catania, Hospital Pharmacy Acireale/Pharmacy Department, Catania, Italy
  3. 3Azienda Sanitaria Provinciale Catania, Pharmacy Department, Catania, Italy

Abstract

Background Italy is one of the European countries where a Risk Sharing Scheme between healthcare institutions and pharmaceutical companies has been widely implemented. It is a new model proposed to accelerate the authorisation and the availability on the market of new drugs. Since September 2007, the Italian drug agency has developed a web register to record data to monitor patients who receive medicines under a Risk Sharing Scheme: the physician prescribes medicines from a list of high-cost oncology drugs and the Italian drug agency validates each prescription and e-mails the hospital pharmacy to release the drug. The non-responding patients are documented in the web register by the health authorities and the pharmacist applies for reimbursement to the pharmaceutical company. Since 2011, Sicily Region has had a hospital pharmacist officially appointed in each pharmacy department to be in charge of obtaining refunds from manufacturers for undocumented non-responding patients and to supervise the pay-back procedures.

Purpose To quantify the amount clawed back from manufacturers after the appointment of the Risk-Sharing pharmacist.

Materials and Methods We detected and examined unresponsive patients recorded in the Registro AIFA-onco. The pay-back procedures were subsequently completed.

Results The number of registered patients increased by 83% and 451 non-documented patients were recorded: 190 Erlotinib, 103 Sorafenib, 57 Sunitinib, 38 Lapatinib, 14 Everolimus, 1 Pemetrexed, 20 Bevacizumab, 20 Cetuximab, 12 Gefitinib, 2 Vinflunine, 16 Lenalidomide, 3 thalidomide, 1 Panitumumab, 7 Bortezomib, 4 Azacitidine, 3 Trabectedin.

The ex-factory expense was €6,340,011.66: €431,063.89 recovered, €145,678.92 is waiting for reimbursement and €136,220.50 has been denied reimbursement.

Conclusions The appointment of a pharmacist enabled us to monitor pay-back procedures and assess responding and non-responding patients reliably.

No conflict of interest.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.